AIM: To evaluate potential pharmacogenetic effects of UGT1A1 polymorphisms on the pharmacokinetics (PK) of dolutegravir (Tivicay®; ViiV Healthcare, NC, USA), an HIV-1 integrase inhibitor. PATIENTS & METHODS: Analysis of pooled data from nine Phase I and II clinical studies was undertaken for 89 subjects receiving repeat dolutegravir 50 mg once daily (tablet formulation) who were genotyped for known UGT1A1 functional variants. RESULTS: Geometric mean ratio (92% CI) for subjects carrying low (*28/*28 and *28/*37) and reduced activity (*1/*6, *1/*28, *1/*37, *28/*36 and *36/*37) polymorphisms compared with subjects with normal activity (*1/*1 and *1/*36) showed decreased oral clearance (CL/F; 0.765 [92% CI: 0.659-0.889]), increased area under the concentration-time curve (AUC(0-τ); 1.307 [1.125-1.518]) and C(max) (1.221 [1.063-1.402]), respectively. CONCLUSION: Increased dolutegravir exposure in carriers of UGT1A1 reduced function polymorphisms is not clinically significant based on accumulated safety data so dose adjustment in these individuals is not required.
AIM: To evaluate potential pharmacogenetic effects of UGT1A1 polymorphisms on the pharmacokinetics (PK) of dolutegravir (Tivicay®; ViiV Healthcare, NC, USA), an HIV-1 integrase inhibitor. PATIENTS & METHODS: Analysis of pooled data from nine Phase I and II clinical studies was undertaken for 89 subjects receiving repeat dolutegravir 50 mg once daily (tablet formulation) who were genotyped for known UGT1A1 functional variants. RESULTS: Geometric mean ratio (92% CI) for subjects carrying low (*28/*28 and *28/*37) and reduced activity (*1/*6, *1/*28, *1/*37, *28/*36 and *36/*37) polymorphisms compared with subjects with normal activity (*1/*1 and *1/*36) showed decreased oral clearance (CL/F; 0.765 [92% CI: 0.659-0.889]), increased area under the concentration-time curve (AUC(0-τ); 1.307 [1.125-1.518]) and C(max) (1.221 [1.063-1.402]), respectively. CONCLUSION: Increased dolutegravir exposure in carriers of UGT1A1 reduced function polymorphisms is not clinically significant based on accumulated safety data so dose adjustment in these individuals is not required.
Authors: Stephanie N Liu; Jessica Bo Li Lu; Christy J W Watson; Philip Lazarus; Zeruesenay Desta; Brandon T Gufford Journal: Drug Metab Dispos Date: 2019-02-25 Impact factor: 3.922
Authors: Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Rohan Gurjar; Laura Dickinson; Daniel Carr; Wolfgang Stöhr; Stefano Bonora; Andrew Owen; Antonio D'Avolio; Adam Cursley; Nathalie De Castro; Gerd Fätkenheuer; Linos Vandekerckhove; Giovanni Di Perri; Anton Pozniak; Christine Schwimmer; François Raffi; Marta Boffito Journal: Pharmacogenomics J Date: 2022-10-20 Impact factor: 3.245